Cargando…

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data

Seamless phase II/III clinical trials are conducted in two stages with treatment selection at the first stage. In the first stage, patients are randomized to a control or one of k > 1 experimental treatments. At the end of this stage, interim data are analysed, and a decision is made concerning w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunz, Cornelia Ursula, Friede, Tim, Parsons, Nick, Todd, Susan, Stallard, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Main Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283755/ https://www.ncbi.nlm.nih.gov/pubmed/24789367 http://dx.doi.org/10.1002/pst.1619

Ejemplares similares

A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints
por: Kunz, Cornelia Ursula, et al.
Publicado: (2015)

Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial
por: Stallard, Nigel, et al.
Publicado: (2015)

Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD
por: Parsons, Nick, et al.
Publicado: (2011)

Should the two‐trial paradigm still be the gold standard in drug assessment?
por: Zhan, Stella Jinran, et al.
Publicado: (2022)

An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information
por: Stallard, Nigel
Publicado: (2011)

Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R
por: Friede, Tim, et al.
Publicado: (2020)

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations
por: Kunz, Cornelia U., et al.
Publicado: (2016)

Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
por: Duputel, Benjamin, et al.
Publicado: (2023)

Estimation after subpopulation selection in adaptive seamless trials
por: Kimani, Peter K., et al.
Publicado: (2015)

A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations
por: Huber, Cynthia, et al.
Publicado: (2019)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

Optimizing the data combination rule for seamless phase II/III clinical trials
por: Hampson, Lisa V, et al.
Publicado: (2015)

Estimation bias in survival data within clinical trials that use adaptive seamless designs
por: Khan, Josephine, et al.
Publicado: (2015)

Reference‐based sensitivity analysis for time‐to‐event data
por: Atkinson, Andrew, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

New insights in Rett syndrome using pathway analysis for transcriptomics data
por: Ehrhart, Friederike, et al.
Publicado: (2016)

A flexible mixed‐data model applied to claims data for post‐market surveillance of prescription drug safety behavior
por: Butler, Harris, et al.
Publicado: (2022)

Using phase II data for the analysis of phase III studies: An application in rare diseases
por: Wandel, Simon, et al.
Publicado: (2017)

Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior
por: Qi, Hongchao, et al.
Publicado: (2022)

Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility
por: Kimani, Peter K, et al.
Publicado: (2013)

Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols
por: Häckl, Sebastian, et al.
Publicado: (2019)

Do single‐arm trials have a role in drug development plans incorporating randomised trials?
por: Grayling, Michael J., et al.
Publicado: (2015)

Practical and robust test for comparing binomial proportions in the randomized phase II setting
por: Attwood, Kristopher, et al.
Publicado: (2021)

A confidence function‐based posterior probability design for phase II cancer trials
por: Shan, Minghua
Publicado: (2020)

Adjusting for treatment selection in phase II/III clinical trials with time to event data
por: Khan, Josephine N., et al.
Publicado: (2022)

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules
por: Robertson, David S., et al.
Publicado: (2016)

SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials
por: Zhang, Yifei, et al.
Publicado: (2022)

Fulfillment of physical activity guidelines in the general population and frailty status in the elderly population: A correlation study of data from 11 European countries
por: Haider, Sandra, et al.
Publicado: (2018)

A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods
por: Bennett, Maxine, et al.
Publicado: (2021)

An alternative method to analyse the biomarker‐strategy design
por: Kunz, Cornelia Ursula, et al.
Publicado: (2018)

Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials
por: Meyer, Elias Laurin, et al.
Publicado: (2022)

A gated group sequential design for seamless Phase II/III trial with subpopulation selection
por: Miao, Guanhong, et al.
Publicado: (2023)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

Doctor David Livingstone
por: Todd, T. R. R., et al.
Publicado: (1974)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g3s2mvrqbaacce7u1i2hm42n85